Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
NCT ID: NCT04809974 Phase: PHASE4 Status: COMPLETED Enrollment: 72 Completion: 2024-02-23
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Summary
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers"). 60% of participants will receive Niagen and 40% will receive PBO. Outcomes will consist of standardized cognitive, neuropsychiatric, physical, functional and biomarker assessments.
Primary Outcome
Effect of Niagen on NAD+ and Cognitive Functioning